M&A: Page 14
-
Kena Betancur via Getty Images
Memic inks SPAC merger, lining up $360M to challenge Intuitive for robotic surgery market
The company is betting the small size of its device and potential to enable more hysterectomies to be done vaginally as differentiators that will enable it to grow sales to $136 million in 2025.
By Nick Paul Taylor • Aug. 16, 2021 -
Philip Morris buys developer of inhaled heart attack drug, ramping up push into healthcare
News of the takeover comes weeks after the tobacco company bought an oral drug delivery specialist and entered into a bidding war to buy inhaled medicine player Vectura. Health charities have pushed back against Philip Morris' foray.
By Nick Paul Taylor • Aug. 10, 2021 -
Medtronic to buy Intersect ENT in $1.1B deal targeting chronic rhinosinusitis market
Intersect ENT's implants, which deliver steroids to open sinus passageways, could position Medtronic to sell products for a condition affecting 35 million U.S. adults.
By Greg Slabodkin • Aug. 6, 2021 -
Carol Highsmith. (2005). "Apex Bldg." [Photo]. Retrieved from Wikimedia Commons.
FTC warns it may challenge deals later as it's hit by 'tidal wave' of merger filings
"Companies that choose to proceed with transactions that have not been fully investigated are doing so at their own risk," the regulator said.
By Samantha Liss • Aug. 5, 2021 -
Hillrom reverses course, will finalize $375M BardyDx acquisition
The decision ends a months-long fight by Hillrom to back out of the buy due to substantially reduced Medicare rate cuts for long-term cardiac monitoring. Hillrom expects the deal to close in the coming weeks.
By Ricky Zipp • Aug. 2, 2021 -
Talk of Baxter-Hillrom tie-up grows as both companies focus on connected care
Hillrom CEO John Groetelaars in a Friday earnings call highlighted the growing importance of connected care, the focus area of Baxter's current M&A strategy. A Baird analyst said it sounded like a non-specific defense of a deal.
By Nick Paul Taylor • Updated July 30, 2021 -
Illumina-Grail merger subject of in-depth EU antitrust probe
European officials opened a three-month investigation of the deal, valued up to $8 billion, due to concerns it may reduce competition in the emerging liquid biopsy market. Illumina vowed to press on.
By Nick Paul Taylor • July 23, 2021 -
Getty / Edited by BioPharma Dive
PacBio inks $800M Omniome buyout to expand into short-read sequencing
The acquisition will give Pacific Biosciences access to early-stage cancer screening and recurrence monitoring markets. The bid comes 18 months after Illumina scrapped plans to acquire PacBio amid regulatory pushback.
By Nick Paul Taylor • July 21, 2021 -
Deep Dive
Medtech M&A expected to be robust in second half after 2021 began with a flurry
Even after deals already eclipsed last year's numbers, analysts predict robust activity in particular among diagnostics companies flush with cash from 2020's COVID-19 test sales.
By Ricky Zipp • July 18, 2021 -
Joe Raedle via Getty Images
Hillrom ordered to complete BardyDx transaction by Delaware court
The court found recent Medicare rate cuts for long-term cardiac wearables did not qualify as a material adverse event, siding with Bardy Diagnostics. However, the judge did not grant BardyDx compensatory damages.
By Ricky Zipp • July 12, 2021 -
Mark Makela via Getty Images
Biden order takes aim at high cost of hearing aids, calls for OTC sales
The executive order issued Friday directs HHS to consider issuing proposed rules within 120 days for allowing hearing aids to be sold over the counter.
By Samantha Liss • Updated July 12, 2021 -
Digital health funding in 2021 smashes last year's record with $14.7B
Coronavirus-spurred momentum in the sector has only accelerated, according to a new Rock Health report.
By Rebecca Pifer • July 7, 2021 -
Boston Scientific spends $295M to snap up rest of cardiac ablation maker Farapulse
The deal adds to the medtech's electrophysiology portfolio in an increasingly competitive space that includes Medtronic and Johnson & Johnson.
By Ricky Zipp • June 24, 2021 -
Pear secures $400M to scale up digital therapeutic business in SPAC deal
The developer of the first three FDA-authorized prescription digital therapeutics has ambitions to grow sales from a projected $4 million this year to $125 million in 2023.
By Nick Paul Taylor • June 23, 2021 -
Roundup: Medtronic's HVAD recall problems continue following patient injuries, deaths
One year after Medtronic pulled the heart pump off the market, there have been two Class I recalls following reports of patient injuries and deaths. Here is a collection of MedTech Dive's coverage of the HVAD saga.
Updated June 27, 2022 -
Courtesy of Humana
Humana acquires Onehome to pursue value-based home health strategy
The deal for Miramar, Florida-based Onehome follows the insurer's recent purchase of home health giant Kindred at Home for $5.7 billion.
By Rebecca Pifer • June 15, 2021 -
Health data giants Ciox, Datavant merge in $7B deal
Real-world health data company Datavant and health record IT firm Ciox Health say combining forces will result in the largest health data ecosystem in the U.S. The merger is supported by investors including J&J and LabCorp.
By Rebecca Pifer • June 10, 2021 -
Medtronic's HVAD controversy
Medtronic's HeartWare HVAD ending brings questions about $1B acquisition
Nearly five years after Medtronic's buy of HeartWare International, the medtech giant pulled the flagship product of the deal due to safety risks, ceding the market to rival Abbott.
By Ricky Zipp • June 8, 2021 -
Abiomed buys preCARDIA to bag breakthrough heart failure device
William Blair analysts had hopes the buy could help Abiomed move past "two years of commercial disruptions" to drive long-term growth.
By Nick Paul Taylor • June 2, 2021 -
Medtronic steps up robotics bet as its challenger to Intuitive starts clinical trial
The medtech giant seeks to double or triple sales in its 2023 fiscal year. However, analysts warned that near-term investments will pressure margins in the short term.
By Nick Paul Taylor • May 28, 2021 -
Adeline Kon/Healthcare Dive/MedTech Dive
PerkinElmer inks $155M Immunodiagnostic buyout, continuing deal spree
The flurry of M&A means PerkinElmer has struck more deals, at a higher aggregate value, in the first six months of 2021 than in the years since it bought Euroimmun for $1.3 billion in 2017.
By Nick Paul Taylor • May 18, 2021 -
Alex Wong via Getty Images
FTC asks Allergan Aesthetics, Soliton for additional information on proposed $550M buyout
The regulator's second request for documentary material, which comes three months after the proposed deal was announced, is part of a deeper probe than its standard review of M&A.
By Nick Paul Taylor • Updated Aug. 11, 2021 -
Mario Tama via Getty Images
NeoGenomics inks $390M Inivata buyout to enter liquid biopsy space
William Blair analysts wrote that NeoGenomics got a good price by setting the buyout fee last year.
By Nick Paul Taylor • May 6, 2021 -
Alex Wong via Getty Images
LabCorp inks $150M takeover of Myriad Genetics autoimmune testing unit
The diagnostics giant discussed its interest in M&A last week, outlining plans to use up to $2 billion in free cash flow to strengthen its businesses through acquisitions.
By Nick Paul Taylor • May 4, 2021 -
MIND_AND_I/iStock / Getty Images via Getty Images
Illumina sues European Commission to block competition probe into Grail buyout
The EU probe is the latest glitch in the takeover bid, which was panned by Wall Street and also faces scrutiny from the FTC. Analysts have said Exact Sciences could benefit from delays.
By Nick Paul Taylor • April 30, 2021
Previous
